ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Georg Kääb contributed 132 entries already.
AstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the study was unlikely to meet its primary endpoints. The setback comes as the company faces growing pressure to deliver new oncology products.
Germany’s Federal Cartel Office has cleared Merck KGaA’s planned acquisition of U.S. life sciences tools company Bio-Techne, removing one of the key regulatory hurdles to the €9.9 billion deal.
The European Commission has revoked the marketing authorization for Tavneos (avacopan) in ANCA-associated vasculitis, citing unreliable efficacy data from the pivotal ADVOCATE trial and serious liver safety concerns. The decision removes Europe’s only approved targeted therapy for the rare autoimmune disease – potentially opening the door for next-generation complement inhibitors.
The Copenhagen-based biomanufacturing company is acquiring Genomatica, bringing Geno’s computational biology and industrial biotech expertise into a platform designed to move from pathway discovery to commercial-scale production. The deal highlights a broader shift in industrial biotech: AI is moving beyond molecule design and into the engineering of how biology is manufactured.
Swiss clinical-stage biotech Vaderis Therapeutics has raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia (HHT). The financing, backed by a broad syndicate of specialist investors, gives the company a potentially decisive runway toward registration for a disease with no approved therapy.
The U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology and preclinical imaging. The deal is another sign that organoids and microphysiological systems are moving from specialized research tools toward integrated platforms for drug discovery.
Swedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. The deal gives Innate funding and a commercial partner for its next clinical step, while adding a late-stage oncology asset to Sobi’s rare-disease portfolio.
Berlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline.
U.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The focus is on extrachromosomal DNA rings.
Consolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, Samsung Biologics aims to strengthen its position in the fast-growing market for complex biopharmaceuticals.